HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants.

AbstractBACKGROUND:
In developing countries, pneumonia and meningitis due to Haemophilus influenzae type b (Hib) are common in children under age 12 months and the mortality from meningitis is high. Protein-polysaccharide conjugate vaccines have brought Hib disease under control in industrialised countries. We did a double-blind randomised trial in The Gambia to assess the efficacy of a Hib conjugate vaccine for the prevention of meningitis, pneumonia, and other invasive diseases due to Hib.
METHODS:
Between March, 1993, and October, 1995, 42,848 infants were randomly allocated the conjugate vaccine Hib polysaccharide tetanus protein (PRP-T) mixed with diphtheria-tetanus-pertussis vaccine (DTP), or DTP alone at age 2 months, 3 months, and 4 months. Children who presented with signs of invasive Hib were investigated by blood culture and, where appropriate, by lumbar puncture, chest radiograph, or percutaneous lung aspirate. Children were followed up for between 5 and 36 months.
FINDINGS:
The median ages at which children received the study vaccine were 11 weeks, 18 weeks, and 24 weeks. 83% of children enrolled received all three doses of vaccine. 17 cases of culture-positive Hib pneumonia, 28 of Hib meningitis, and five of other forms of invasive Hib disease were detected amongst the study children. The efficacy of the vaccine for the prevention of all invasive disease after three doses was 95% (PRP-T vaccinees 1, controls 19 [95% CI 67-100]), for the prevention of Hib pneumonia after two or three doses, 100% (vaccinees 0, controls 10 [55-100]), and for the prevention of radiologically defined pneumonia at any time after enrollment, 21.1% (PRP-T vaccinees 198, controls 251 [4.6-34.9]).
INTERPRETATION:
PRP-T conjugate Hib vaccine prevented most cases of meningitis and pneumonia due to Hib in Gambian infants. The reduction in the overall incidence of radiologically defined pneumonia in PRP-T vaccinees suggests that about 20% of episodes of pneumonia in young Gambian children are due to Hib. The introduction of Hib vaccines into developing countries should substantially reduce childhood mortality due to pneumonia and meningitis.
AuthorsK Mulholland, S Hilton, R Adegbola, S Usen, A Oparaugo, C Omosigho, M Weber, A Palmer, G Schneider, K Jobe, G Lahai, S Jaffar, O Secka, K Lin, C Ethevenaux, B Greenwood
JournalLancet (London, England) (Lancet) Vol. 349 Issue 9060 Pg. 1191-7 (Apr 26 1997) ISSN: 0140-6736 [Print] England
PMID9130939 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Diphtheria-Tetanus-Pertussis Vaccine
  • Haemophilus Vaccines
  • Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate
  • Tetanus Toxoid
  • Vaccines, Conjugate
Topics
  • Age Factors
  • Developing Countries
  • Diphtheria-Tetanus-Pertussis Vaccine (administration & dosage)
  • Double-Blind Method
  • Follow-Up Studies
  • Gambia
  • Haemophilus Infections (diagnosis, prevention & control)
  • Haemophilus Vaccines (administration & dosage)
  • Haemophilus influenzae (classification)
  • Humans
  • Immunization Schedule
  • Incidence
  • Infant
  • Meningitis, Haemophilus (diagnosis, prevention & control)
  • Paracentesis
  • Pneumonia, Bacterial (diagnosis, prevention & control)
  • Radiography, Thoracic
  • Spinal Puncture
  • Tetanus Toxoid (administration & dosage)
  • Vaccines, Conjugate (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: